Last updated: July 31, 2026
Methylergonovine maleate is a mature generic uterotonic used primarily to prevent or treat postpartum hemorrhage caused by uterine atony. Its U.S. market is small in revenue but strategically important because the drug is used in acute hospital care, has limited therapeutic substitutes, and can face supply disruption when only a few manufacturers remain active. The product has no meaningful remaining composition-of-matter exclusivity. Commercial performance depends on hospital purchasing, generic competition, manufacturing reliability, and obstetric hemorrhage demand rather than patent protection.
What is methylergonovine maleate used for?
Methylergonovine maleate is an ergot alkaloid that produces sustained uterine contraction. FDA labeling indicates use for routine management of uterine atony and hemorrhage after delivery, including after placental delivery and in selected postabortion settings [1].
The principal dosage forms are:
| Dosage form |
Typical strength |
Primary setting |
Commercial position |
| Injection |
0.2 mg/mL |
Hospital, labor and delivery, operating room |
More strategically important because it is used during acute bleeding |
| Tablet |
0.2 mg |
Postpartum outpatient treatment |
Lower-value, retail and institutional generic market |
Methylergonovine is generally administered after delivery when oxytocin has not produced an adequate response or when a longer-lasting uterotonic effect is required. It is contraindicated in patients with hypertension, toxemia, preeclampsia, and pregnancy before delivery because of its vasoconstrictive effects [1].
The drug is not a biologic, complex drug-device combination, or controlled substance. Biosimilar competition is therefore irrelevant. Competitive pressure comes from generic uterotonics and hospital protocol selection.
What is the FDA regulatory status of methylergonovine maleate?
Methylergonovine maleate has long-standing FDA approval as an oral tablet and injectable product. The reference product, Methergine, was approved decades ago, and the market is now supplied primarily through generic approvals and legacy branded or authorized-generic channels [1][2].
FDA-regulated products include:
- Methylergonovine maleate tablets, typically 0.2 mg.
- Methylergonovine maleate injection, typically 0.2 mg/mL.
- Products approved through abbreviated new drug applications, where the applicant demonstrates bioequivalence to the reference product.
- Institutional products supplied through hospital and wholesaler channels.
The regulatory pathway is favorable for new entrants because the active ingredient, dosage forms, and clinical use are established. A new generic manufacturer generally does not need to repeat the full clinical development program required for a novel uterotonic. The principal development work involves pharmaceutical equivalence, bioequivalence where applicable, chemistry, manufacturing and controls, and facility compliance.
What is the Orange Book status of methylergonovine maleate?
The commercial market is not protected by a live, commercially significant patent estate comparable to that of a recently approved drug. Public FDA product information does not indicate a current patent barrier that would prevent an ANDA applicant from entering the tablet or injection market [2].
The relevant legal position is:
| Protection category |
Current commercial relevance |
| Composition-of-matter patent |
Expired or no longer relevant |
| Basic method-of-use protection |
Expired or unavailable for generic blocking |
| Formulation patents |
No widely recognized blocking estate for standard 0.2 mg products |
| Pediatric exclusivity |
Not a current market barrier |
| New chemical entity exclusivity |
Expired decades ago |
| Orphan exclusivity |
Not applicable |
| Biosimilar exclusivity |
Not applicable |
The absence of a meaningful Orange Book patent barrier does not guarantee rapid entry. A prospective applicant still faces FDA review, manufacturing validation, sterile-product controls for injection, and commercial scale requirements.
When does methylergonovine maleate lose exclusivity?
Methylergonovine maleate lost meaningful regulatory and patent exclusivity many years ago. The underlying drug predates the modern Hatch-Waxman exclusivity system, and the product is now a mature generic medicine.
No credible commercial analysis should assign a future “loss-of-exclusivity” date to the active ingredient. The relevant market event is generic supply participation, not patent expiry. Market share can shift when an approved manufacturer exits, returns after a shortage, changes its wholesaler strategy, or loses manufacturing capacity.
The practical exclusivity timeline is:
| Period |
Market event |
| Historical |
Original Methergine development and approval |
| Post-Hatch-Waxman era |
Generic tablet and injection approvals |
| Current market |
Mature, low-price generic competition |
| Forward outlook |
Supply consolidation and procurement-driven price changes |
How many patents cover methylergonovine maleate?
No active patent portfolio appears to provide broad blocking protection for standard methylergonovine maleate tablets or injections. Any historic patents associated with the active ingredient, original product, or basic therapeutic use would have expired long ago.
The remaining intellectual-property exposure is more likely to involve:
- Manufacturing processes.
- Packaging and container systems.
- Device or administration features, if a manufacturer develops a differentiated presentation.
- Private-label or contractual rights.
- Trademarks associated with Methergine or manufacturer names.
These rights would not normally prevent a conventional ANDA applicant from marketing an equivalent tablet or injection if the applicant satisfies FDA requirements.
Are there Paragraph IV challenges to methylergonovine maleate?
A major current Paragraph IV dispute is unlikely because the product does not depend on a live patent estate. Paragraph IV litigation is most relevant when an ANDA applicant certifies that a listed patent is invalid, unenforceable, or will not be infringed. For a mature drug with no meaningful blocking patents, applicants generally face a standard generic approval pathway rather than a high-value patent challenge.
The litigation risk profile is therefore different from that of newer drugs:
| Risk category |
Methylergonovine maleate exposure |
| Paragraph IV patent litigation |
Low |
| Patent-settlement risk |
Low |
| ANDA approval risk |
Moderate, depending on manufacturing and FDA review |
| Product-liability risk |
Present because the drug is used during acute hemorrhage |
| Supply-chain litigation |
Possible but not a principal market driver |
| Trademark disputes |
Limited to branded products and labeling |
What formulations are protected by methylergonovine maleate patents?
Standard tablets and injectable solutions do not appear to have a commercially meaningful active formulation patent estate. The core products are technically established dosage forms:
- Immediate-release 0.2 mg tablets.
- Sterile 0.2 mg/mL injectable solution.
- Conventional packaging for hospital and outpatient use.
The injectable form creates a higher manufacturing barrier than the tablet because the product must meet sterile manufacturing, particulate, assay, stability, container-closure, and release-testing requirements. That barrier is operational rather than patent-based.
A new formulation, such as a novel controlled-release system or an improved delivery device, could theoretically create new patent opportunities. Such a product would require evidence that the formulation offers a meaningful clinical, safety, adherence, or operational advantage. No such formulation has established a major commercial position in the standard U.S. market.
How does methylergonovine compare with competing uterotonics?
Methylergonovine competes within a protocol-driven postpartum hemorrhage market. Its main alternatives include oxytocin, misoprostol, carboprost tromethamine, and tranexamic acid. These products are not interchangeable in all patients because contraindications, onset, route, and clinical context differ.
| Drug |
Main role |
Key limitation |
Commercial implication |
| Oxytocin |
First-line uterotonic in many deliveries |
Requires infusion or injection and may be insufficient alone |
High routine volume |
| Methylergonovine |
Sustained uterine contraction after delivery |
Contraindicated in hypertension and preeclampsia |
Lower volume, acute-care value |
| Carboprost tromethamine |
Treatment of refractory atony |
Respiratory and other adverse-effect concerns |
Selective hospital use |
| Misoprostol |
Alternative uterotonic, including where injectables are limited |
Variable tolerability and route considerations |
Low-cost substitution pressure |
| Tranexamic acid |
Antifibrinolytic used in postpartum hemorrhage |
Not a direct uterotonic |
Expands protocol competition |
Methylergonovine retains clinical value because it provides a distinct pharmacologic mechanism and is familiar to obstetric teams. Its market is limited by the prevalence of hypertensive disorders of pregnancy and the availability of other agents.
Which companies manufacture or distribute methylergonovine maleate?
The U.S. market has included multiple generic manufacturers, contract manufacturers, repackagers, and hospital suppliers over time. Manufacturer participation can change because generic products are often discontinued, transferred, relabeled, or temporarily unavailable.
For commercial diligence, the relevant company categories are:
- FDA-approved ANDA holders.
- Sterile injectable manufacturers.
- Tablet manufacturers.
- Hospital repackagers.
- Wholesale distributors and group purchasing organizations.
- Authorized generic or legacy branded-product suppliers.
DailyMed listings identify the manufacturer and labeling entity for specific marketed presentations, while FDA’s Drugs@FDA and Orange Book databases identify approval and product-status information [2][3]. Manufacturer count should be measured by active, orderable National Drug Codes rather than historical FDA approvals. A high number of approved applications can overstate effective competition if only a small number of suppliers have current production.
What patent litigation affects methylergonovine maleate?
There is no prominent current patent litigation affecting the standard U.S. methylergonovine maleate market. The product’s litigation exposure is more likely to arise from:
- Product-liability claims related to hypertension, ischemia, or dosing.
- Manufacturing or sterility allegations involving injection products.
- Drug-shortage obligations and supply contracts.
- Labeling or advertising disputes.
- Hospital procurement and distributor agreements.
The low patent-litigation profile reduces legal launch risk for generic entrants. It does not eliminate FDA compliance risk, especially for sterile injectable manufacturing.
What generic entry risks exist for methylergonovine maleate?
Generic entry is legally straightforward but commercially difficult. The main barriers are low expected revenue, limited hospital demand, sterile manufacturing requirements, and procurement concentration.
Manufacturing and IP barriers
For tablets, the technical barrier is modest. For injection, the barrier is higher because the applicant must maintain validated sterile production and reliable supply of active pharmaceutical ingredient and packaging components. A new entrant may also need to qualify its product with hospital systems and distributors.
The commercial return may not justify entry unless the applicant has:
- Existing sterile injectable capacity.
- A broad hospital portfolio.
- An established distribution network.
- A contract supply agreement.
- A strategy for shortage-prone products.
The absence of patent protection can increase competition while reducing the expected price premium available to a new manufacturer.
What is the financial trajectory for methylergonovine maleate?
Methylergonovine maleate is a mature, low-revenue generic product. Public companies generally do not report it as a separate revenue line, so product-level financial performance must be inferred from volume, pricing, product availability, and portfolio disclosures rather than issuer-reported sales.
The financial trajectory has four phases:
| Phase |
Financial pattern |
| Branded period |
Higher unit economics and limited direct competition |
| Generic conversion |
Rapid price compression and broader supplier participation |
| Mature generic period |
Low unit prices, stable clinical demand, limited innovation |
| Supply-constrained period |
Temporary price increases and share gains for available suppliers |
Revenue is driven primarily by units sold. Demand is linked to delivery volume, postpartum hemorrhage incidence, hospital protocols, and product availability. Pricing is shaped by group purchasing organizations, hospital tenders, wholesaler contracts, and the number of active suppliers.
The injection may generate better strategic value than the tablet because hospitals prioritize dependable access to acute-care injectables. That does not necessarily translate into high annual sales. A manufacturer can gain disproportionate commercial importance from a product with modest revenue if competitors are unable to maintain supply.
Revenue exposure and investment relevance
The product is unlikely to be a material revenue driver for a diversified pharmaceutical company. Its value is higher in these situations:
- A generic company has excess sterile capacity.
- A supplier holds a hospital portfolio and can bundle products.
- A manufacturer benefits from a temporary shortage.
- An investor is evaluating generic supply-chain resilience.
- A distributor is assessing obstetric emergency-product availability.
Long-term price growth is constrained by generic substitution and the lack of patent protection. Upside depends on supply disruption, market exit by competitors, regulatory approval of a differentiated presentation, or expanded institutional purchasing.
What is the outlook for methylergonovine maleate generic launch scenarios?
A new tablet entrant would likely face intense price competition and limited differentiation. A new injectable entrant could gain share if it offers reliable availability, competitive hospital pricing, and strong sterile manufacturing performance.
| Launch scenario |
Expected market effect |
| Additional tablet supplier |
More price pressure, limited share displacement |
| Additional injection supplier |
Greater resilience if capacity is reliable |
| Existing supplier exit |
Temporary shortage risk and pricing volatility |
| FDA warning or recall |
Rapid hospital switching and distributor reallocation |
| New delivery system |
Potential differentiation, but higher development cost |
| Supply agreement with hospital network |
More predictable volume and lower commercial risk |
The most attractive entry strategy is generally portfolio-based rather than product-specific. Methylergonovine can function as one product within a broader obstetric or injectable hospital portfolio.
How strong is the patent estate for methylergonovine maleate?
The patent estate is weak from a blocking perspective and offers little defensive value. The product’s competitive protection comes from manufacturing execution, supply continuity, regulatory compliance, and institutional relationships.
| Patent-estate factor |
Assessment |
| Blocking composition patent |
None of practical current significance |
| Formulation protection |
Limited for standard products |
| Method-of-use protection |
Expired or nonblocking |
| Manufacturing know-how |
More relevant for injection |
| Regulatory exclusivity |
Expired |
| Commercial moat |
Supply reliability and hospital access |
Geographic protection is also limited. Patent expiry has removed most jurisdictional barriers in major generic markets. Local regulatory approvals, sterile manufacturing standards, procurement rules, and reimbursement systems now determine market access.
Key Takeaways
- Methylergonovine maleate is a mature generic uterotonic used mainly for postpartum hemorrhage and uterine atony.
- The U.S. market includes tablets and 0.2 mg/mL injections.
- No meaningful active patent estate appears to block conventional generic entry.
- Paragraph IV litigation and patent-settlement risk are low.
- Injection manufacturing is the main operational barrier, particularly sterile production and supply continuity.
- Revenue is low relative to innovative pharmaceuticals and is generally not disclosed separately by diversified manufacturers.
- Demand is stable but narrow, while pricing is constrained by generic competition and hospital procurement.
- Supplier exits, shortages, recalls, and sterile-capacity constraints can create temporary commercial opportunities.
- Biosimilar risk does not apply because methylergonovine maleate is a small-molecule generic drug.
- The product has greater strategic value within a hospital injectable portfolio than as a standalone growth asset.
FAQs
Is methylergonovine maleate still sold in the United States?
Yes. Methylergonovine maleate remains available in generic tablet and injectable presentations, although product availability can vary by manufacturer and channel.
Is Methergine the same as methylergonovine maleate?
Yes. Methergine is the historical brand name, while methylergonovine maleate identifies the active pharmaceutical ingredient and salt form.
Can methylergonovine maleate be substituted with oxytocin?
Not automatically. Oxytocin and methylergonovine have different pharmacology, contraindications, dosing, and clinical roles. Substitution is determined by the treating clinician and institutional protocol.
Does methylergonovine maleate have a shortage-driven investment thesis?
Only in a limited sense. A shortage can create temporary pricing and share opportunities for an available supplier, but the underlying product has low structural growth and little patent-based upside.
What is the largest commercial risk for a methylergonovine maleate manufacturer?
For injection products, the largest risk is usually loss of reliable sterile supply, followed by FDA manufacturing action, product recall, or inability to secure hospital and distributor contracts.
References
-
U.S. Food and Drug Administration. (2023). Methylergonovine maleate injection, USP prescribing information. FDA-approved labeling.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
National Library of Medicine. (2024). DailyMed: Methylergonovine maleate drug labeling. https://dailymed.nlm.nih.gov/dailymed/
-
World Health Organization. (2017). WHO recommendations for prevention and treatment of postpartum haemorrhage. World Health Organization.
